Vaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of “Buy” from Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have earned an average rating of “Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $147.50.

A number of analysts recently weighed in on the stock. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a report on Friday, December 20th. They issued a “buy” rating and a $135.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. Finally, Guggenheim reiterated a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, March 12th.

Vaxcyte Stock Performance

Vaxcyte stock opened at $68.56 on Friday. Vaxcyte has a 52 week low of $58.10 and a 52 week high of $121.06. The firm has a market cap of $8.83 billion, a P/E ratio of -14.90 and a beta of 1.02. The business’s fifty day moving average is $80.72 and its two-hundred day moving average is $93.16.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. On average, equities research analysts predict that Vaxcyte will post -4.21 earnings per share for the current year.

Insider Buying and Selling at Vaxcyte

In related news, Director Teri Loxam sold 6,250 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares in the company, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $83.66, for a total transaction of $669,280.00. Following the sale, the chief operating officer now owns 205,695 shares in the company, valued at $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 46,250 shares of company stock valued at $3,840,018. Corporate insiders own 3.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in PCVX. Atria Investments Inc bought a new stake in Vaxcyte in the 3rd quarter valued at $286,000. CIBC Asset Management Inc raised its stake in shares of Vaxcyte by 3.6% in the 3rd quarter. CIBC Asset Management Inc now owns 3,136 shares of the company’s stock valued at $358,000 after purchasing an additional 110 shares during the period. Natixis Advisors LLC lifted its holdings in shares of Vaxcyte by 61.1% in the third quarter. Natixis Advisors LLC now owns 22,697 shares of the company’s stock valued at $2,594,000 after purchasing an additional 8,606 shares in the last quarter. Pathstone Holdings LLC boosted its position in shares of Vaxcyte by 7.6% during the third quarter. Pathstone Holdings LLC now owns 30,527 shares of the company’s stock worth $3,488,000 after buying an additional 2,154 shares during the period. Finally, B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Vaxcyte during the third quarter worth about $1,189,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.